Background and Objectives
Some evidence of efficacy has been found for omega-3 fatty acids in patients with borderline personality disorder (BPD). In a previous 12-week randomized trial we assessed the efficacy of the combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with valproic acid, in comparison with valproic acid monotherapy, in 43 BPD outpatients. Combined therapy was superior to valproic acid monotherapy (the control group) in the treatment of some BPD symptoms: impulsive–behavioral dyscontrol, outbursts of anger, and self-harm. The present study is a 24-week follow-up aimed at evaluating whether the differences in efficacy between the two subgroups were maintained after discontinuation of omega-3 fatty acids.
Thirty-four patients who completed the 12-week trial entered the follow-up study. Participants were evaluated at the beginning and at the end of the follow-up period using the rating scales that showed a significant difference between the groups after the 12-week trial with fatty acids supplementation: the Borderline Personality Disorder Severity Index (BPDSI) (items ‘impulsivity’ and ‘outbursts of anger’), Barratt Impulsiveness Scale–Version 11 (BIS-11), and Self Harm Inventory (SHI). Statistical analysis was performed with analysis of variance (ANOVA) for repeated measures.
At the end of the follow-up a significant difference within groups was maintained for all four variables examined, while a significant difference between groups was maintained for outbursts of anger. Concerning tolerability, no clinically significant adverse effects were registered during the follow-up period.
Combined therapy with omega-3 fatty acids showed long-lasting effects after discontinuation in terms of anger control.
The trial was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR) and allocated the code: ACTRN12612001150831.
This is a preview of subscription content,to check access.
Access this article
Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5:67.
Grant R, Guest J. Role of omega-3 PUFAs in neurobiological health. Adv Neurobiol. 2016;12:247–74.
Casula M, Soranna D, Catapano AL, Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl. 2013;14(2):243–51.
Berger G, Bozzatello P, et al. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5(8):69. https://doi.org/10.3390/jcm5080069.
Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18(2):89–101.
Buydens-Branchey L, Branchey M. Long chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. Psychiatry Res. 2008;157(1–3):95–104.
Amminger GP, Schäfer MR, Schlogelhofer M, Klier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934. https://doi.org/10.1038/ncomms8934.
Bellino S, Bozzatello P, Rocca G, Bogetto F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol. 2014;28(2):125–32.
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR). 4th ed. Washington, DC: APA; 2000.
First MB, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Washington, DC: American Psychiatric Press; 1997.
First MB, Gibbon M, Spitzer RL. Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington, DC: American Psychiatric Press; 1997.
Arntz A, Van den Hoorn M, Cornelis J, Verheul R, Van den Bosch WM, De Bie A. Reliability and validity of the borderline personality disorder severity index. J Personal Disord. 2003;17:45–59.
Barratt ES. Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep. 1965;16:547–54.
Sansone RA, Wiederman MW, Sansone LA. The Self-harm Inventory (SHI): development of a scale for identifying self-destructive behaviors and borderline personality disorder. J Clin Psychol. 1998;54:973–83.
Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. https://doi.org/10.1002/14651858.CD005653.pub2.
Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, et al. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest. 1996;97(4):1129–33.
Hamazaki T, Thienprasert A, Kheovichai K. The effect of docosahexaenoic acid on aggression in elderly Thai subjects—a placebo-controlled double-blind study. Nutr Neurosci. 2002;5(1):37–41.
Garland MR, Hallahan B. Essential fatty acids and their role in conditions characterised by impulsivity. Int Rev Psychiat. 2006;18(2):99–105.
Gunderson JG. Revising the borderline diagnosis for DSM-V: an alternative proposal. J Pers Disord. 2010;24(6):694–708.
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest
Paola Bozzatello, Paola Rocca, and Silvio Bellino declare that they have no conflicts of interest.
About this article
Cite this article
Bozzatello, P., Rocca, P. & Bellino, S. Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. Clin Drug Investig 38, 367–372 (2018). https://doi.org/10.1007/s40261-017-0617-x